Oragenics, Inc. (ORNI) Clinical Trial Demonstrates Dental Health Benefits of EvorKids® in Cavity-prone Children
Oragenics, a nutraceutical company focused on oral care probiotics for humans and companion pets, today announced the completion of an independently conducted clinical trial for EvorKids®, the company’s branded product designed to support oral health in children ages 3 to 11. The randomized, double-blind study enrolled 60 six- to 12-year old children prone to tooth decay/cavity (caries). The study evaluated baseline levels of key oral bacterial species mutans Streptococci and Lactobacilli, which are recognized as risk factors to the development of caries. After four weeks of treatment of EvorKids®, Oragenis reports that results show a statistically significant decrease from baseline…